Sigrid V. Carlsson, MD, PhD, MPH, presented “Who Needs a Prostate Biopsy? Risk-stratification Strategies Before Prostate Biopsy” during the 24th Future Directions in Urology Symposium in August 2024 in Colorado Springs, Colorado.
How to cite: Carlsson, Sigrid V. “Who Needs a Prostate Biopsy? Risk-stratification Strategies Before Prostate Biopsy.” August 2024. Accessed Nov 2025. https://grandroundsinurology.com/who-needs-a-prostate-biopsy-risk-stratification-strategies-before-prostate-biopsy/
Who Needs a Prostate Biopsy? Risk-stratification Strategies Before Prostate Biopsy – Summary
Sigrid V. Carlsson, MD, PhD, MPH, discusses the evolving paradigm in prostate cancer diagnostics, moving away from the traditional model where an elevated prostate-specific antigen (PSA) level directly leads to a biopsy. In this 8-minute talk, she emphasizes the importance of incorporating risk stratification methods before proceeding to biopsy, which helps reduce unnecessary interventions.
Dr. Carlsson discusses current guidelines that recommend using MRI as part of the initial biopsy strategy, with a more mandatory role in repeat biopsy settings if it has not previously been performed. Risk calculators provide a cost-effective and accessible means to estimate the likelihood of high-grade disease, further refining the decision-making process.
The presentation also highlights the rapid advancement in biomarkers and the integration of artificial intelligence (AI) in improving MRI interpretation and enhancing prostate cancer diagnostics’ accuracy and efficiency.
The Future Directions in Urology Symposium (FDUS) is an annual urology think tank and non-CME educational summit that brings together industry figures and experts to discuss the current state of genitourinary care and define future directions in treatment. Dr. Dreicer delivered this educational activity during the 24th iteration of the meeting in August 2024 in Colorado Springs, Colorado.
ABOUT THE AUTHOR
Sigrid V. Carlsson, MD, PhD, MPH, is the Division Head of the Clinical Epidemiology of Early Cancer Detection at DKFZ German Cancer Research Center in Heidelberg, Germany. Her research focuses on developing risk-stratified approaches to screening, diagnosis, treatment, and follow-up.
